Join BJS Academy
BJS Academy>Randomized clinical ...>Ultrasound assisted ...
Normal View Dyslexic View

Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial.

26 January 2023
Randomized clinical trials Breast
Zhang L, Cheng M, Lin Y, Zhang J, Shen B, Chen Y et al.

Br J Surg 2022; 109: 1232–1238.

In this study that included 330 women, the sentinel node identification rate was similar: 94.5 per cent with ultrasound assistance versus 95.8 per cent with dual tracer. Number of sentinel nodes, number of metastatic nodes and duration of surgery were similar between the groups.

Comment: Ultrasound-assisted carbon nanoparticle mapping was non inferior.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct142
Randomized clinical trials
Randomized clinical trials
Breast
Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial.
Zhang L, Cheng M, Lin Y, Zhang J, Shen B, Chen Y et al.
26012023
Br J Surg 2022; 109: 1232–1238.
In this study that included 330 women, the sentinel node identification rate was similar: 94.5 per cent with ultrasound assistance versus 95.8 per cent with dual tracer. Number of sentinel nodes, number of metastatic nodes and duration of surgery were similar between the groups.
Comment: Ultrasound-assisted carbon nanoparticle mapping was non inferior.
Published on: 26 January 2023
Article ID: rct142

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!